Merck beats first-quarter expectations on Keytruda, Gardasil strength

Drugmaker Merck & Co Inc (MRK.N) on Thursday posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.